Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis
- 1 July 2004
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 117 (2) , 87-92
- https://doi.org/10.1016/j.amjmed.2004.02.032
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugsJournal of Hepatology, 2002
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)Annals of the Rheumatic Diseases, 2002
- Guidelines for the management of rheumatoid arthritis: 2002 UpdateArthritis & Rheumatism, 2002
- Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazineAnnals of the Rheumatic Diseases, 2001
- Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexateArthritis & Rheumatism, 2001
- Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid ArthritisAnnals of Internal Medicine, 2001
- Serious liver disease in a patient receiving methotrexate and leflunomideArthritis & Rheumatism, 2000
- Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritisArthritis & Rheumatism, 2000
- Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central MassachusettsPharmacoepidemiology and Drug Safety, 1999
- Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapyThe American Journal of Medicine, 1987